Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypoxia-Targeted Oncology and Ischemic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HIF-1 Alpha (HIF1A) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human HIF1A Protein (bHLH-PAS domains or ODD-mutant P402A/P564A to resist normoxic degradation). High purity (>95%), Endotoxin Controlled, Sequence Verified. | View HIF1A Products |
| Gene Delivery | HIF1A Promise-ORF / Lentivirus. Full-length ORF (WT or constitutively active double mutant) for stable cell line construction and reporter gene assays. | View HIF1A Products |
| Benchmark Ab | Anti-HIF1A Recombinant Antibody. High affinity, sequence-verified positive control for Western Blot, IHC, and ChIP assays. | View HIF1A Products |
| Validator | HIF1A siRNA Set. Target-specific knockdown duplexes for validation of target specificity and pathway downstream response. | View HIF1A Products |
| Related Target A | VHL (Von Hippel-Lindau) E3 ligase substrate recognition subunit crucial for validating HIF1A-targeting PROTACs and molecular glues. |
View VHL Products |
| Related Target B | ARNT (HIF-1 Beta) Dimerization partner of HIF1A. Essential for screening protein-protein interaction (PPI) inhibitors. |
View ARNT Products |
| Related Target C | EGLN1 (PHD2) Prolyl hydroxylase that regulates HIF1A degradation; key target for anemia and ischemic tissue therapeutics. |
View EGLN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Normoxic Instability of Wild-Type HIF1A | Constitutively active mutant proteins (P402A/P564A) designed to resist oxygen-dependent degradation in normoxic assay conditions. |
| Protein-Protein Dimerization Screening | High-purity bHLH-PAS domain-specific truncation proteins optimized for robust ARNT interaction screening. |
| Lack of Controls for Target Degradation | Sequence-verified clinical benchmark antibodies and validated siRNA sets included for precise assay calibration. |
| Expression and Glycosylation Fidelity | HEK293 expressed options available to preserve native post-translational modifications. |
Live HIF-1 Alpha R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HIF-1 Alpha therapeutics is intensifying, with major players shifting focus from traditional small-molecule transcription inhibitors to targeted protein degradation (PROTACs) and gene-silencing therapeutics. As first-generation direct inhibitors navigate clinical challenges, the next wave of R&D is targeting the specific protein-protein interfaces (such as HIF1A/ARNT and HIF1A/p300) and leveraging targeted ubiquitination pathways to selectively eliminate the protein in highly hypoxic tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Molecular Glues | Arvinas, Kymera Therapeutics | Solid Tumors, Refractory Cancers | Ternary complex validation assays requiring high-purity VHL and stabilized HIF1A proteins. |
| Small Molecule PPI Inhibitors | Eli Lilly, Merck | Renal Cell Carcinoma, Glioblastoma | Dimerization assays requiring structural-grade HIF1A-PAS domain and ARNT proteins. |
| siRNA / Antisense (ASO) | Alnylam, Ionis Pharmaceuticals | Metastatic Solid Tumors | Target knockdown confirmation using validated siRNA sets and high-affinity detection antibodies. |
| PHD Inhibitors (Activators) | AstraZeneca, FibroGen | Anemia, Ischemia, Wound Healing | In vitro hydroxylation assays requiring high-purity EGLN1 (PHD2) and wild-type HIF1A ODD domain peptides. |